Clinically, the expression level of PROX1 combined with that of SIRT3 may be a useful prognostic biomarker in CRC, and targeting the PROX1-EZH2 complex axis might be a useful therapeutic strategy for CRC treatment. This evidence concerns the gene SIRT3 and colorectal carcinoma.